Corporate Reorganization and Re-Focused Strategy Propels Advancement San Diego, CA – October 31, 2023 – Okogen, an ophthalmic biotechnology company, today announced the initiation of a Phase IIb clinical trial evaluating OKG-0303 for Acute Infectious Conjunctivitis (“Pink Eye”) to be conducted in

Lead candidate, OKG-0502, to address significant unmet medical need. San Diego, CA and Melbourne, AUS – March 8, 2022 – Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Moriarty will

Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and efficacy of OKG-0301 in the treatment of acute adenoviral conjunctivitis.

Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and efficacy of OKG-0301 in the treatment of acute adenoviral conjunctivitis.

Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance the ongoing development of the company’s lead candidate for viral conjunctivitis (commonly known as pink eye), OKG-0301.

Okogen, Inc., a developer of ophthalmic anti-infectives, received a notice of allowance from the United States Patent and Trademark Office for the use of ranpirnase for the treatment of viral conjunctivitis. “The claims granted under 3IPOK1.0002US, in combination with the our existing in-licensed portfolio, further reinforce our strong intellectual property position,” said Brian M. Strem, Ph.D., Chief Executive Officer of Okogen.

Okogen, Inc., a developer of ophthalmic anti-infectives has secured Ora, Inc., the leading ophthalmic Contract Research Organization, to conduct the clinical studies and lead the regulatory strategy of OKG-0301 for the treatment of adenoviral conjunctivitis.